Review Article
Metastatic Squamous Cell Carcinoma of the Anus: Time for a Shift in the Treatment Paradigm?
Table 1
Phase II chemotherapy trials of metastatic squamous cell carcinoma of the anus.
| | Author | Number of patients | Agents | Response rate | Median PFS (months) | OS (months) |
| | Wilking et al. [13] | 15 | Vincristine, bleomycin, and high-dose methotrexate | 3/12 (25%) | 2 | NR | | Hainsworth et al. [14] | 60 (7 with anal cancer) | Paclitaxel, carboplatin, and infusional 5FU | 65% overall 4/7 (57%) anal patients | 35 overall (26 anal patients) | NR | | Jhawer et al. [15] | 20 | Mitomycin C, adriamycin, cisplatin, and bleomycin-CCNU | 12/20 (60%) | 8 | 15 |
|
|
